Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

February 2025

Molecular pathology selected abstracts

February 2025—Excision repair cross-complementation group two (ERCC2) is a tumor-suppressor gene involved in DNA repair. Compound heterozygous mutations in ERCC2 are linked to rare recessive disorders, such as xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy, all of which are characterized by ultraviolet light sensitivity. Somatic ERCC2 mutations in cancers, particularly bladder cancers, have emerged as significant prognostic markers. The mutations predict platinum sensitivity and correlate with favorable outcomes in patients with bladder cancer, but they have not been identified as independent prognostic indicators due to a lack of data, resulting from limited cohort sizes. The authors conducted a study in which they investigated the impact of ERCC2 hotspot mutations on genomewide mutagenesis and their implications for cancer prognosis and therapeutic stratification.

Q&A column

February 2025
Q. Is a pathology review on all cerebrospinal fluid (CSF) specimen differential slides necessary? Should the review be based on the number of white blood cells counted or the abnormality of the differential, or both? Read answer.

Q. At what level or time is aPTT considered incorrect? Is an aPTT of less than 22.0 seconds an acceptable result? Read answer.

Newsbytes

February 2025—When NYU Langone Health began focusing on digital pathology last year, it also began focusing on people—those it would need to keep such a program humming along. “When we were setting up this operation, it was pretty obvious to me that I wanted to have a dedicated team of people that are going to focus just on digital pathology,” says Rui Soares, anatomic pathology operations director at NYU Langone, a multisite system with approximately 80 pathologists at four hospitals. It would be “unfair,” he adds, to expect laboratory assistants to learn and perform such specialized tasks while performing other duties.

Put It on the Board

February 2025—Roche’s whole slide imaging system, Roche Digital Pathology Dx, received an additional 510(k) clearance from the Food and Drug Administration. This latest clearance modifies the one Roche received in June 2024 for Roche Digital Pathology Dx, which includes the Ventana DP 200 slide scanner.